Improved Excessive Daytime Sleepiness with Selegiline in Parkinson’s Disease: An Open Trial

Improved Excessive Daytime Sleepiness with Selegiline in Parkinson‘s Disease: An Open Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045946

Enrollment

Unknown

Registered

2021-04-30

Start date

2020-03-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Diseases

Interventions

Selegiline Group:Selegiline

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 30 to 80 years; 2. Diagnosis of idiopathic PD according to the UK Parkinson s Disease Society Brain Bank criteria; 3. Epworth Sleepiness Scale (ESS) > 7; 4. No cognitive impairment, defined by Mini-Mental State Exam score <= 26; 5. Stable dose of anti-Parkinson drugs for at least 30 days. No use of MAO-B inhibitors within the preceding 4 weeks; 6. Good compliance, able to independently complete the study evaluation.

Exclusion criteria

Exclusion criteria: 1. Diagnosis of atypical Parkinsonian syndrome, vascular Parkinsonism or drug-induced Parkinsonism; 2. PD Patients with other neurological and/or psychiatric disorders; 3. Shift-work, which cannot ensure a stable sleep-wake cycle habits; 4. Participating in other PD intervention drugs or management programs; 5. Contraindications to selegiline.

Design outcomes

Primary

Measure	Time frame
Epworth Sleepiness Scales;	—

Secondary

Measure	Time frame
Parkinson's Disease Sleepness Scales;Parkinson's Disease Patients Dairy Questionaires;	—

Countries

China

Contacts

Public ContactLiu Chunfeng

The Second Affiliated Hospital of Soochow University

liuchunfeng@suda.edu.cn+86 512 67783307

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026